Artivion Q2 2026 Earnings: Revenue Growth Came With a GAAP Loss

Artivion (NYSE: AORT) reported Q2 2026 revenue of $125.8 million, up 11% from $113.0 million a year earlier, while diluted EPS moved to a loss of $0.28 from earnings of $0.03. On-X and aortic stent grafts led sales growth, but higher operating expenses pushed the company to a GAAP operating loss, and quarterly free cash flow turned negative.

Core financial results

Revenue increased 9% on a non-GAAP constant-currency basis. Gross profit rose about 10%, although gross margin narrowed by approximately 70 basis points to 64.0%.

The larger change was in operating expenses. General, administrative and marketing expense increased by $22.2 million to $79.8 million, while research and development expense rose by $2.0 million to $9.1 million. As a result, Artivion moved from an operating profit to an operating loss despite higher revenue.

Business and product performance

Aortic stent grafts and On-X were the principal growth engines. Together, these categories contributed about $11.5 million, or roughly 90%, of Artivion’s total year-over-year revenue increase.

The contrast between the faster-growing categories and the rest of the portfolio remained pronounced. Surgical sealants were flat on a reported basis and declined 2% at constant currency, while preservation services grew only 1% at constant currency.

Geographically, all reported regions produced constant-currency growth. North America increased 8%, Europe, the Middle East and Africa grew 10%, Asia Pacific rose 9%, and Latin America increased 11%.

Acquisition and other adjustments widened the GAAP/non-GAAP gap

Artivion reported EBITDA of only $1.9 million but adjusted EBITDA of $26.4 million. The reconciliation included $15.5 million of business development, integration and severance expense, $8.2 million of non-cash compensation and a $0.7 million foreign-currency revaluation loss.

The company’s adjusted G&A expense was $60.0 million, up from $53.4 million. This indicates that expenses increased even after removing the identified business development, integration and severance items. Adjusted EBITDA grew in dollars, but its margin declined to approximately 21.0% from 21.9%.

Adjusted net income also moved in a different direction from adjusted EBITDA, falling to $6.3 million from $10.7 million. Adjusted diluted EPS declined to $0.13 from $0.24, and the current-quarter result included the $0.7 million pretax foreign-currency revaluation loss.

Cash flow and balance sheet

Quarterly operating cash flow declined to negative $1.3 million from positive $15.0 million. Capital expenditures increased to $10.7 million from $3.3 million, with both factors contributing to the $12.0 million free cash flow deficit.

During the first six months of 2026, Artivion spent $116.7 million, net of acquired cash, on Endospan and raised $148.9 million through net long-term debt issuance. Net long-term debt consequently increased to $363.4 million at June 30 from $215.1 million at the end of 2025. Cash and cash equivalents rose to $77.3 million from $64.9 million, while inventory increased to $103.4 million from $92.4 million.

Product and regulatory milestones

Artivion completed its acquisition of Endospan and the NEXUS Aortic Arch Stent Graft System during the quarter. It also received U.S. FDA premarket approval for the AMDS Hybrid Prosthesis.

Management views NEXUS, AMDS and ARCEVO LSA as a three-part aortic arch portfolio. CEO Pat Mackin also described NEXUS as a platform supporting three additional premarket approval programs, while enrollment in the ARTIZEN program was proceeding as expected.

Full-year guidance

Artivion reiterated rather than raised its 2026 outlook. Management’s confidence was supported by the quarter’s product growth, the AMDS approval and the return to growth across international regions, but the guidance continues to incorporate expenses associated with Endospan.

The adjusted EBITDA outlook includes approximately $8 million of expected 2026 expense associated with Endospan. The revenue growth comparison uses adjusted 2025 revenue, which excludes a $2.3 million reserve related to estimated payments to the Italian government.

Recent insider transactions

The supplied six-month insider summary reports 536,927 shares classified as purchases and 177,044 shares classified as sales, producing net purchases of 359,883 shares. The latest reported transactions include stock awards and a derivative conversion, so the aggregate should not be interpreted entirely as open-market buying.

The eight May 18 awards went to Marna P. Borgstrom, Anthony B. Semedo, Elizabeth A. Hoff, Jon W. Salveson, Thomas F. Ackerman, Jeffrey H. Burbank, Daniel J. Bevevino and James W. Bullock. These transactions alone do not establish insiders’ views about the company’s prospects.

Risks investors should monitor

• Expense and margin pressure: Revenue growth did not prevent a GAAP operating loss, and adjusted EBITDA margin narrowed even after excluding several costs.
• Cash flow weakness: Operating cash flow turned negative while capital expenditures increased. Continued negative free cash flow would make the company’s higher debt balance more consequential.
• Endospan integration and leverage: The acquisition expanded Artivion’s product portfolio but also contributed to higher expenses and a substantial increase in long-term debt.
• Concentration of growth: On-X and aortic stent grafts generated roughly 90% of the quarterly revenue increase, while surgical sealants and preservation services recorded limited or negative constant-currency growth.
• Commercial and regulatory execution: Future benefits depend on commercializing AMDS, integrating NEXUS and advancing additional clinical and regulatory programs on the expected timelines.

Summary

Artivion’s second-quarter revenue growth was concentrated in On-X and aortic stent grafts, supported by growth across all geographic regions. However, higher operating costs, a wide gap between GAAP and adjusted results, and negative free cash flow offset part of that progress. The next points to monitor are expense control, Endospan integration, cash generation and whether the expanded aortic arch portfolio can sustain growth without further margin pressure.